Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00737204 · ClinicalTrials.gov registry record · Phase 4

Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS

A Phase 4 study, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 4
Development phase
70
Enrollment target

NCT00737204 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 70 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00737204, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 4
Development phase
70 participants
Enrollment target

Study Summary

This study will determine whether armodafinil (Nuvigil), an FDA approved medication, is effective in reducing fatigue in adults with HIV/AIDS.

Interventions

  • DRUG Placebo
  • DRUG Armodafinil

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2008-06
Est. Completion 2010-09
Phase Phase 4

What the Registry Record Tells You About NCT00737204

The ClinicalTrials.gov registry entry for NCT00737204 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00737204 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00737204 about?

NCT00737204 is a clinical study titled "Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS". This study will determine whether armodafinil (Nuvigil), an FDA approved medication, is effective in reducing fatigue in adults with HIV/AIDS.

What is the current status of trial NCT00737204?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2008-06. Estimated completion is 2010-09.

What interventions are being tested in trial NCT00737204?

The interventions under investigation include: Placebo (DRUG), Armodafinil (DRUG).

Who is sponsoring clinical trial NCT00737204?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.